Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesClinical/Medical PolicyPresbyterian InVisionFirst Coverage | OpenPayer
    Ask Trek AI about this page
    CurrentPresbyterian Health PlanPolicy 39.1

    Genetic Testing, InvisionFirst Liquid Biopsy for Lung Cancer

    Customize your policy alerts

    Sign up for Presbyterian Health Plan Policy 39.1 alerts

    Get alerted when Policy 39.1 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Coverage and prior authorization for blood-based InVisionFirst ctDNA liquid biopsy testing supporting therapeutic decisions in advanced NSCLC for Commercial, Medicaid, and Medicare members, subject to the member-specific benefit plan and policy criteria.

    Policy Summary
    PayerPresbyterian Health Plan
    PolicyGenetic Testing, InvisionFirst Liquid Biopsy for Lung Cancer
    Policy CodePolicy 39.1
    Change TypeClarified
    Effective DateNov 27, 2025
    Last ReviewMay 20, 2026
    Next Review DateApr 8, 2027
    Key ActionObtain prior authorization through Pres Online before submitting InVisionFirst testing.
    SourceLink
    POLICY UPDATE CHANGES

    The 2026 annual review clarified that plasma ctDNA testing is not medically necessary for initial NSCLC diagnosis and is covered only when invasive tissue biopsy is medically inappropriate or tissue is insufficient for molecular analysis.

    Commercial, Medicaid, MedicareLines of business with coverage
    Stage IIIB/IVAdvanced disease stage addressed
    2Listed billing codes
    PA required

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Utilization management requirement
    ExcludedInitial diagnosis

    Coverage Criteria

    InVisionFirst-Lung Coverage

    InVisionFirst®-Lung blood-based liquid biopsy testing is covered when ALL applicable criteria are met:

    ALL of the following

    • The patient has advanced (Stage IIIB or IV) non-small cell lung cancer (NSCLC).
    • The test is being used to support therapeutic decisions.
    • ONE of the following

      • The patient is not medically appropriate for invasive tissue biopsy.
      • Insufficient tissue is available for molecular analysis, or tissue-based testing is otherwise unobtainable.

    Plasma ctDNA liquid biopsy testing should not replace tissue-based diagnosis.

    Plasma ctDNA liquid biopsy testing is not medically necessary for the initial diagnosis of NSCLC.

    Coding Reference

    Covered and non-covered codes listed for referenceCPT
    81479InVisionFirst®-Lung, ctDNA Liquid biopsy testing for 36 or 37 genes relevant to advanced NSCLC
    0388UOncology (non-small cell lung cancer), next-generation sequencing with identification of single nucleotide variants, copy number variants, insertions and deletions, and structural variants in 37 cancer-related genes, plasma, with report for alteration detection
    Advanced NSCLC Stage
    Advanced NSCLC stageStage IIIB/IV
    Cancer typeNon-small cell lung cancer (NSCLC)
    Testing contextAdvanced disease
    Gene Content
    Gene coverage36 or 37 genes relevant to advanced NSCLC
    Code 0388U gene content37 cancer-related genes
    Testing method under code 0388UNext-generation sequencing of plasma

    Provider Actions and Authorization

    Prior Authorization

    Prior Authorization Required

    Prior authorization is required for applicable InVisionFirst® testing. Submit the request through Pres Online: https://ds.phs.org/preslogin/index.jsp.

    • Maintain the prior authorization requirement for CPT/PLA code 0388U.
    Documentation Required

    Document Medical Necessity and Tissue Availability

    Submit documentation supporting medical necessity and the applicable coverage criteria. Providers are expected to maintain or have access to documentation when requested, including records showing why invasive tissue biopsy is not medically appropriate or why insufficient tissue is available for molecular analysis.

    • Document advanced disease status and the patient’s tissue-availability circumstances.
    • Provide additional information supporting medical necessity when the criteria are not clearly met.

    Clinical Background

    InVisionFirst-Lung is a blood-based circulating tumor DNA (ctDNA) liquid biopsy that evaluates cancer-related molecular alterations relevant to advanced non-small cell lung cancer (NSCLC). Results may support therapeutic decisions when tissue-based molecular testing cannot be performed under the applicable policy criteria.

    Test Definition

    InVisionFirst-Lung
    Test nameInVisionFirst-Lung
    Specimen and methodBlood-based circulating tumor DNA liquid biopsy testing
    Alterations evaluatedAlterations in 36 or 37 genes relevant to advanced NSCLC

    Covered Indications

    Advanced Stage IIIB/IV NSCLC Covered Indication

    Covered when all of the following criteria are met.

    Covered indication

    • Advanced disease: The patient has advanced Stage IIIB/IV non-small cell lung cancer.Stage IIIB/IV NSCLC
    • Therapeutic decision-making: Blood-based InVisionFirst-Lung ctDNA testing is needed to support therapeutic decisions.
    • Tissue-based molecular testing is infeasible: Tissue-based molecular analysis cannot be performed because tissue is insufficient or unobtainable, or invasive tissue biopsy is medically inappropriate.Tissue insufficient, unobtainable, or biopsy medically inappropriate

    Eligibility Requirements

    Tissue-based molecular analysis must be infeasible before plasma ctDNA testing may qualify for coverage. This requirement is met when tissue is insufficient or unobtainable for molecular analysis, or when an invasive tissue biopsy is medically inappropriate.

    Not Covered

    Plasma ctDNA testing is not covered as medically necessary for the initial diagnosis of NSCLC. It is also not covered when used as a replacement for tissue-based diagnosis; the policy supports its use only in qualifying circumstances when tissue-based molecular testing is infeasible.

    Policy Summary
    PayerPresbyterian Health Plan
    PolicyGenetic Testing, InvisionFirst Liquid Biopsy for Lung Cancer
    Policy CodePolicy 39.1
    Change TypeClarified
    Effective DateNov 27, 2025
    Last ReviewMay 20, 2026
    Next Review DateApr 8, 2027
    Key ActionObtain prior authorization through Pres Online before submitting InVisionFirst testing.
    SourceLink
    On This Page
    Coverage CriteriaCoding ReferenceProvider Actions and AuthorizationClinical BackgroundTest DefinitionCovered IndicationsEligibility RequirementsNot Covered
    Denial Risk

    Initial or Replacement Tissue Diagnosis Not Medically Necessary

    Plasma ctDNA (liquid biopsy) testing is not medically necessary for the initial diagnosis of non-small cell lung cancer (NSCLC) and should not replace a tissue-based diagnosis.

    • Do not use the test to establish the initial diagnosis of NSCLC.
    • Do not use the test as a replacement for a tissue diagnosis.
    Denial Risk

    Criteria Not Met May Result in Noncoverage

    Coverage may be denied when the coverage criteria are not met. InVisionFirst® is intended for advanced (Stage IIIB/IV) NSCLC when tissue is unavailable because tissue material is insufficient or unobtainable for tissue-based molecular analysis, or when the patient is not medically appropriate for invasive tissue biopsy.

    • Disease stage must be advanced (Stage IIIB/IV) NSCLC.
    • Tissue must be unavailable because it is insufficient or unobtainable, or invasive biopsy must not be medically appropriate.
    • Molecular analysis using tissue must not be feasible because adequate tissue is unavailable.
    Denial Risk

    Prior Authorization Not Obtained

    Failure to obtain the required prior authorization before applicable testing may result in noncoverage.

    • Submit the request through Pres Online before testing is performed.
    • The prior authorization requirement applies to CPT/PLA code 0388U.